Effects of D-cycloserine on negative symptoms in schizophrenia.
about
Glutamatergic drugs for schizophreniaAugmentation treatment of psychotherapy for anxiety disorders with D-cycloserineD-Cycloserine in Neuropsychiatric Diseases: A Systematic ReviewProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaD-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trialD-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window.Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.Developing therapeutics for schizophrenia and other psychotic disorders.Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo.Effects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related BehaviorA new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of strokeAugmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brainA randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disordersPersistent negative symptoms in schizophrenia: an overview.D-serine as a gliotransmitter and its roles in brain development and disease.Extinction memory is impaired in schizophreniaA NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus.Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Management of schizophrenia in late life with antipsychotic medications: a qualitative review.Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?Pharmacological treatment of negative symptoms in schizophrenia.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.Neuroinflammation-Induced Memory Deficits Are Amenable to Treatment with D-Cycloserine.Natural Medicines for Psychotic Disorders: A Systematic Review.A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q24246163-3047AFFE-56FC-4839-B72D-DBD1052BEEF8Q24684778-17F27315-86C7-4B29-9838-8B2FB9249612Q26781321-0A28176B-EC74-4358-A18C-80CAC41E1A84Q28240120-46B28CA0-3912-448C-8D10-09C0225AF6C8Q28248687-F5505D48-A3E4-458D-BB1D-0E4B1374CC0BQ28396812-FA29D9F4-56F1-436F-9163-9AF6CB2EC73BQ30450078-100A88D1-0713-452E-B4AF-B4D63E5C4A6FQ33615809-000680C5-BCAE-4D7C-BC6B-2EDF0325977AQ33891806-BF286F7F-16BA-4DE2-8B42-5F07131168F8Q33900951-A2CA8111-AE8D-4F6E-BF65-BF2C17D6353BQ33946985-F1861A63-A6D2-44BB-A80D-35066C358CF4Q34013820-8F3F8B24-4753-4DC8-B48C-60E29F933FBBQ34286452-B921EF10-4329-454F-8DC3-A62D36A2AAE7Q34653628-DFB0F907-ADC7-405F-AF99-B3C0F0BDCEC0Q35588323-4D4934D2-1B46-42E7-B7F9-4809C7571D10Q36394299-EE9FB36B-24CB-4BA1-B14F-F0AA6C95FD5BQ36461648-14DB6AC6-07A0-4407-B4B6-1783AD1503A1Q36651056-A3D7A652-774E-492E-9713-8DA2DA3368BEQ36785486-87E4B811-E6C4-4057-9A34-4D775BCFBE39Q37087825-5520B4DA-D090-448E-A7AF-8772C0B8AD4BQ37141200-91CACAB6-34E7-4BFB-AF04-22BB3AC44521Q37621271-A30297C0-AD84-413F-8EC5-CC1BB12D7E3DQ37662441-A496A0E6-EB1B-40F6-B692-D9BCF9AE92E7Q37960898-7D35F2E2-984F-4A1F-A50C-6929A33CCBAFQ38173359-E7A75D9A-521B-4827-B88E-7693E29B507DQ38431333-E44C5CE9-DF3D-4A2E-9C7D-C1C226FF22CBQ38669576-85F01D4B-2A09-42C4-8591-1EE777813B2EQ38750121-A083845C-5AB2-47FB-B428-E8C37DB920F5Q43118502-B38DBB6A-B22C-4C97-931D-38AF09B75C09Q48621584-A3336771-4364-45FC-B6E6-1E7834CD2826Q49363880-0A0FD3FB-E965-42EA-9F8E-0505EF8071DAQ50695785-0D6DD724-8EF8-4E07-AD45-7CC631550151Q58561523-67E9A125-5130-4425-B517-27D164503BC4
P2860
Effects of D-cycloserine on negative symptoms in schizophrenia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Effects of D-cycloserine on negative symptoms in schizophrenia.
@ast
Effects of D-cycloserine on negative symptoms in schizophrenia.
@en
type
label
Effects of D-cycloserine on negative symptoms in schizophrenia.
@ast
Effects of D-cycloserine on negative symptoms in schizophrenia.
@en
prefLabel
Effects of D-cycloserine on negative symptoms in schizophrenia.
@ast
Effects of D-cycloserine on negative symptoms in schizophrenia.
@en
P2093
P1476
Effects of D-cycloserine on negative symptoms in schizophrenia.
@en
P2093
Alena Kunzova
Burt Angrist
Dragana Bugarski-Kirola
Eric Peselow
Erica J Duncan
John P Rotrosen
June Corwin
Marion P Schwartz
Myrsini Stephanides
Sandor Szilagyi
P304
P356
10.1016/J.SCHRES.2004.03.013
P407
P577
2004-12-01T00:00:00Z